secwatch.observer — SEC 8-K summary
======================================

Issuer:     IVERIC bio, Inc. (—)
CIK:        0001410939
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001104659-23-079843
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Astellas completes $5.9B acquisition of IVERIC bio; shareholders receive $40.00 per share
--------------------------------------------------------------------------------

- Merger completed July 11, 2023; each IVERIC share converted to $40.00 cash.
- Aggregate purchase price ~$5.9B, funded by Astellas via cash and credit.
- Board of directors resigned at effective time; replaced by sole director/officer from Merger Sub.
- IVERIC to delist from Nasdaq and deregister shares with SEC.
- Credit agreement with Hercules Capital repaid in full and terminated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410939/000110465923079843/0001104659-23-079843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410939/000110465923079843/tm2320976d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-079843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer